49 results on '"Kebriaei, P"'
Search Results
2. Proton Versus Photon Craniospinal Irradiation for Hematologic Malignancies Involving the CNS: Effectiveness and Toxicity in the Setting of Stem Cell Transplant
3. Graft-Versus-Host Disease Following Radiation Therapy in Patients With a History of Allogeneic Stem Cell Transplant
4. Myeloablative Timed Sequential Busulfan Is Safe in Patients With Relapsed or High-Risk Multiple Myeloma
5. A Randomized Phase III Trial Of Busulfan + Melphalan (Bu-Mel) Vs Melphalan Alone For Multiple Myeloma: Longer PFS In The Bu-Mel Arm
6. The Impact of Pre-Transplant Valganciclovir on Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplant
7. Thiotepa (Tt), Busulfan (Bu), and Clofarabine (Clo) as a Conditioning Therapy for Allogeneic Hematopoetic Stem Cell Transplant for Patients with High Risk Malignancies: Updated Response and Engraftment Data
8. NaïVe Cd19-Specific T Cells Exhibit Superior Proliferation and Potential for Adoptive Immunotherapy
9. Comparison of Busulfan + Melphalan to Melphalan 200 mg/m2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma
10. Assessing Sleeping Beauty Transpositions for T-Cell Immunotherapy by Supercomputer-Based High-Throughput Profiling of Integration Events
11. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)
12. Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin'S Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant
13. Immediate Adverse Events Following infusion of ex vivo-Expanded Cord Blood for Stem Cell Transplantation
14. Haploidentical Stem Cell Transplantation for Minorities
15. The Incidence and Natural History of Pure Red Cell Aplasia in Major ABO Mismatched Hematopoietic Stem Cell Transplantation in Patients Receiving Modern Reduce Intensity and Reduced Toxicity Regimens
16. Faster Lymphocyte Recovery After Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts For Decreased Non-Relapse Mortality (NRM) In Adults With Acute Lymphoblastic Leukemia (ALL)
17. Clofarabine ± Fludarabine With IV Busulfan And Allogeneic Stem Cell Transplantation For Relapsed, Refractory Myeloid Leukemia (ML) And MDS
18. Imatinib Maintenance Following Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Philadelphia Chromosome Positive (PH+) Acute Lymphoblastic Leukemia (ALL)
19. Safety Of T-Cell Replete Haploidentical Stem Cell Transplantation Using Fludarabine, Melpahalan And Thiotepa Conditioning And High-Dose Post-Transplant Cyclophosphamide
20. Addition Of Bortezemib To High Dose Melphalan Does Not Improve Response Rate Or Progression-Free Survival
21. Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD
22. The Role Of Donor-Specific Anti-HLA Antibodies (DSA) In Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors
23. High Rate Of De Novo Chronic Graft-Versus-Host (cGVHD) Following Busulfan-Fludarabine Conditioning And Allogeneic Stem Cell Transplantation From A Matched-Sibling Donor (MSD) For AML/MDS
24. Inferior Outcome With Addition Of Rituximab For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Acute Lymphoblastic Leukemia (ALL)
25. Use of Palifermin in Allogeneic Stem Cell Transplantation (SCT) for Patients with Acute Lymphoblastic Leukemia (ALL)
26. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen
27. Impact of Cytogenetics and Marrow Remission Status on Disease Progression in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Stem Cell Transplantation
28. Allogeneic Stem Cell Transplantation (Allo-SCT) For Relapsed, Refractory Myeloid Leukemia and Mds Using Clofarabine (Clo) ± Fludarabine (Flu) with IV Busulfan (Bu) As Conditioning Therapy
29. An Analysis of the Charges Associated With Peripheral Blood Hematopoietic Progenitor Cell (HPC) Mobilization, Collection and Cryopreservation In Patients With Lymphomas Undergoing Autologous Stem Cell Transplantation
30. Improved Outcome for Allogeneic Transplantation Performed After January 2000
31. Sequential Therapy With Nonablative Allogeneic Stem Cell Transplantation, Post Transplant Imatinib and Donor Lymphocyte Infusion for Chronic Myeloid Leukemia
32. Reduced Intensity Conditioning (RIC) Regimen Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients (PTS) With Acute Lymphoblastic Leukemia (ALL)
33. Outcomes Of Allogeneic Stem Cell Transplantation for Patients With Acute Leukemia Transformed from Myelofibrosis
34. Selective Reprogramming of Cd19-Specific T Cells With IL-21 and CD28 Signaling for Adoptive Immunotherapy of Acute Lymphoblastic Leukemia
35. Post-Hematopoietic Stem Cell Transplantation (HSCT) Outcomes in Patients With AML Transplanted Prior to Achieving Platelet Recovery
36. Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation
37. Development and Comparison of Limited Sampling Strategies for Pharmacokinetically-Guided High-Dose, Intravenous Busulfan
38. High Throughput Non-Viral Gene Transfer of T Cells by Micro-Electroporators to Generate CD19-Specific Cells for Immediate Infusion
39. 266: Usefulness of Bronchoscopic Lavage in Intensive Care Unit for Critically Ill Stem Cell Transplant Recipients with Pulmonary Infiltrates
40. 96: Incidence and Factors Influencing Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)
41. 392: Fundamental nursing responsibilities in mesenchymal stem cell infusion
42. 306: Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD)
43. 296: Etanercept as salvage therapy for chronic graft-versus-host disease
44. 20: Autologous stem cell transplantation for elderly patients with multiple myeloma
45. 19: Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma
46. Salvage autologous transplantation in multiple myeloma
47. Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for stem cell transplantation (SCT) in patients (pts) with advanced lymphoid malignancies
48. Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma
49. Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.